Henry Chen  

Henry has more than 30 years of experience in investment banking, private equity, and venture capital.  

Henry spent the first part of his professional career in New York City.  He started his journey in Smith Barney's Debt Originations Group  (now Citigroup Inc.’s Global Corporate & Investment Banking Group).   Later, he joined BBVA to work with financial and industrial clients in South America.  He has since shifted his focus to Asia and was a Venture Partner at VantagePoint Capital, based in Beijing and Managing Partner at Aspiro Capital, a venture capital firm based in Taipei.

As an entrepreneur, Henry co-founded OptiPhar, a fintech start-up that focused on the acquisition and securitization of adjudicated pharmacy receivables; and GTLpetrol which planned to build, own and operate multi-billion-dollar industrial complexes that would convert natural gas to synthetic petroleum.   He was CFO for Accelerated Biosciences, which is working on the commercialization of the human trophoblast stem cell (hTSC).  He also co-founded and is the CEO of Double Helix Labs, the sponsor for Nucleo DAO, which is working on the intersection of Web3 and healthcare big data.  And he founded, and is currently focused on, Aexo Biosciences, which is commercializing extra-cellular vesicles derived from the hTSC.

Henry holds an M.B.A. in Finance and Technology from the Leonard N. Stern School of Business of New York University and a B.S.E in Electrical Engineering from the University of Pennsylvania.